40 completed, 6 terminated, 5 unknown, 1 withdrawn. 52 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 52 | Completed 40, Terminated 6, Unknown 5, Withdrawn 1 |
Follow ziprasidone: new trials by email Literature Review of ziprasidone trials Research Report on ziprasidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Clozapine, Antipsychotics,Other (non-Clozapine) - Treatment-resistant Schizophrenia | Phase 4 | Terminated | Ohio State University | 5 | 2023-08-16 | 2026-02-25 |
| Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building Risperidone, Aripiprazole, Ziprasidone - Schizophrenia | Phase 4 | Unknown | Shanghai Mental Health Center | 350 | 2021-05-01 | 2020-08-26 |
| The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Ziprasidone - Schizophrenia | Phase 4 | Unknown | Yang Fude | 1000 | 2016-10-01 | 2016-10-18 |
| Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Olanzapine, Amisulpride, Risperidone - Schizophrenia, Schizophrenia and Disorders With Psychotic Features | Phase 4 | Completed | Technical University of Munich | 21 | 2015-02-01 | 2018-10-11 |
| Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc) - Schizophrenia | Phase 4 | Unknown | Matt Byerly | 200 | 2014-12-01 | 2015-06-08 |
| Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Lithium, Valproate, Oxcarbazepine - Bipolar Disorder | Phase 4 | Unknown | Guiyun Xu | 120 | 2013-09-01 | 2015-03-17 |
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain Ziprasidone, aripiprazole, quetiapine, or risperidone - High Risk MC4R Genotype, Low Risk MC4R Genotype | Phase 4 | Terminated | Northwell Health | 14 | 2013-07-01 | 2016-02-05 |
| Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad) ziprasidone - Medication Adherence, Bipolar Disorder | Phase 4 | Completed | University Hospitals Cleveland Medical Center | 30 | 2011-01-01 | 2014-12-30 |
| Effectiveness of Ziprasidone for Patients With Schizophrenia Ziprasidone - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | Soonchunhyang University Hospital | 67 | 2010-09-01 | 2014-11-19 |
| Antipsychotics and Gene Expression in Soft Tissues olanzapine, ziprasidone, placebo - Schizophrenia, Diabetes | Phase 4 | Completed | Medical University of Vienna | 16 | 2010-07-01 | 2017-03-23 |
| Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Ziprasidone, Placebo - Bipolar Disorder, Panic Disorder | Phase 4 | Completed | VA Palo Alto Health Care System | 49 | 2010-04-01 | 2025-04-08 |
| Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder ziprasidone, Sugar pill - Depression, Bipolar Disorder | Phase 4 | Completed | Tufts Medical Center | 49 | 2010-02-01 | 2017-02-24 |
| Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome Ziprasidone, Aripiprazole - Schizophrenia | Phase 4 | Completed | University of Malaya | 175 | 2009-05-01 | 2012-11-27 |
| Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Antipsychotics - Schizophrenia or Schizoaffective Disorder | Phase 4 | Unknown | University of Sao Paulo | 126 | 2009-04-01 | 2009-11-19 |
| An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression ziprasidone hydrochloride, placebo - Depression, Bipolar | Phase 4 | Completed | Queen's University | 14 | 2009-02-01 | 2015-12-16 |
| Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine - Psychotic Disorders | Phase 4 | Completed | Johns Hopkins University | 127 | 2009-01-01 | 2017-04-25 |
| One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome Ziprasidone HCL (oral) - Schizophrenia and Disorders With Psychotic Features | Phase 4 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 172 | 2008-12-01 | 2021-03-03 |
| Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up Aripiprazole, Quetiapine, Ziprasidone - Schizophrenia, Psychotic Disorders | Phase 4 | Completed | Fundación Marques de Valdecilla | 203 | 2008-10-01 | 2017-03-14 |
| Ziprasidone vs Standard Therapy for Agitated Patients in the ED ziprasidone, Standard therapy - Psychosis, Agitation | Phase 4 | Withdrawn | George Washington University | 2008-09-01 | 2017-09-25 | |
| Ziprasidone in Pediatric Bipolar Disorder Ziprasidone - Bipolar Disorder | Phase 4 | Completed | Baylor College of Medicine | 28 | 2007-02-01 | 2019-10-22 |
Showing 20 of 52. Sign in to see all of them.
Schizophrenia (31) · Psychotic Disorders (20) · Bipolar Disorder (12) · Metabolic Syndrome (4) · Depression (2) · Diabetes Mellitus (2) · Generalized Anxiety Disorder (2) · Insulin Resistance (2) · Mania (2) · Medication Adherence (2) · Psychomotor Agitation (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Weight Gain (2) · Affective Disorders, Psychotic (1) · Anxiety Disorders (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (11) · Fundación Marques de Valdecilla (3) · Northwell Health (3) · Massachusetts General Hospital (2) · Medical University of Vienna (2) · Baylor College of Medicine (1) · Bronx Psychiatric Center (1) · Central Institute of Mental Health, Mannheim (1) · Charite University, Berlin, Germany (1) · Chonbuk National University Hospital (1) · Creighton University (1) · Eli Lilly and Company (1) · George Washington University (1) · Guiyun Xu (1) · Icahn School of Medicine at Mount Sinai (1)
United States (23) · Spain (6) · Germany (5) · Brazil (4) · China (3) · Greece (3) · Turkey (Türkiye) (3) · Austria (2) · Canada (2) · South Korea (2) · Egypt (1) · Hungary (1) · Italy (1) · Jordan (1) · Kuwait (1)
Benedicto Crespo-Facorro, Professor (3) · Ahmad Hatim Sulaiman, MBBS,MPM (1) · Anusha Baskaran, BScH (1) · Ashwin Patkar, MD (1) · Christoph Correll, MD (1) · David C Henderson, MD (1) · Frederick Petty, MD, PhD (1) · Gloria Reeves, MD (1) · Guinyun Xu, M.D (1) · Han Yong Jung, MD, PhD (1) · Jeffrey A Lieberman, MD (1) · Jeffrey Grace, MD (1) · Jonathan M. Meyer, MD (1) · Joseph Biederman, MD (1)
PMID 29856773, PMID 30097769, PMID 16172203, PMID 16247923, PMID 16585434, PMID 16585435, PMID 17151158, PMID 17151159, PMID 19640511, PMID 20334680, PMID 20816031, PMID 20868641, PMID 20879830, PMID 21041245, PMID 21536693, PMID 21884578, PMID 22000938, PMID 22290266, PMID 22316567, PMID 22480442, PMID 23235268, PMID 23246610, PMID 23295604, PMID 23422376, PMID 23727135, PMID 24028745, PMID 24030617, PMID 24079855, PMID 24183751, PMID 24345758, PMID 24400912, PMID 24490070, PMID 24524169, PMID 24568177, PMID 24569099, PMID 24581550, PMID 24630140, PMID 24717389, PMID 24726579, PMID 24850369, PMID 24862257, PMID 24870446, PMID 25075930, PMID 25562591, PMID 25567425, PMID 25668654, PMID 25679125, PMID 26443050, PMID 26475577, PMID 26479222
K23MH074540 (1), N01MH090001 (1), N01MH90001 (1), R01MH059312 (1), R01MH060845 (1), R01MH080270 (1), U01MH070007 (1), U01MH070008 (1), U01MH070009 (1), U01MH070010 (1), U01MH070011 (1), U01MH070012 (1), U01MH070016 (1), U01MH070017 (1), U01MH070023 (1)